We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Novel Rapid Lateral Flow Immunoassay Can Function as `Suitcase Laboratory` for On-Site Detection of COVID-19

By LabMedica International staff writers
Posted on 11 Dec 2020
Scientists have developed a novel amplification-free rapid SARS-CoV-2 nucleic acid detection platform based on hybrid capture fluorescence immunoassay (HC-FIA) to fulfill the need for rapid and accurate nucleic acid detection at the point of care.

The use of the monoclonal antibody S9.6 is the distinctive feature of this process developed by scientists from the Suzhou Institute of Biomedical Engineering and Technology (Suzhou, China). More...
The process recognizes DNA-RNA double-stranded hybrids and enables the conversion of nucleic acid testing into immunofluorescence on a simple lateral flow dipstick. The whole test procedure involves two steps, namely hybridization and immunofluorescence analysis, and it can be finished in less than an hour.

The process uses optimized DNA probes to target the conserved open reading frame 1ab, envelope protein and the nucleocapsid regions of the SARS-CoV-2 genome derived from clinical throat swab samples. It can achieve a limit of detection of 500 copies/mL, comparable to commercial kits based on real-time quantitative polymerase chain reaction (qPCR). In addition, no significant cross-reaction has been found between the SARS-CoV-2 probes and 55 common pathogens. The performance of the HC-FIA detection reagent is free of interference by hemoglobin, mucin and various possible drugs that might exist in clinical samples. The assay and test kit can also be adapted for the detection of other viral RNA.

The HC-FIA process was supported by a multi-hospital randomized double-blind trial involving 734 samples. The current research not only represents proof-of-concept, but also has resulted in development of a commercial test kit for the diagnosis of SARS-CoV-2. The test kit was recently approved by the National Medical Products Administration and received European Conformity certification. The test kit requires little in terms of equipment and professional personnel to confirm infection. It can function as a "suitcase laboratory" and thus be used as an on-site detection method for outpatient departments, emergency departments, customs and grassroots disease control.

"We are confident that the HC-FIA test is capable of serving as a sure safeguard in containing the epidemic through reducing community spread and imported cases, especially in developing countries," said WANG Daming, lead researcher of the study.

Related Links:
Suzhou Institute of Biomedical Engineering and Technology


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Thyroid Test
Anti-Thyroid EIA Test
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.